A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07043400)
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer and Research Centers Chandler Ii — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (95 Sites)
Showing the first 25 of 95 sites.
- Ironwood Cancer and Research Centers Chandler Ii — Chandler, Arizona
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- UC Health Cancer Care and Hematology Clinic Memorial Hospital Central — Colorado Springs, Colorado
- Bioresearch Partners Holding Hialeah Hospital — Hialeah, Florida
- Orlando Health Cancer Institute Downtown Orlando — Orlando, Florida
- Northwestern University — Chicago, Illinois
- Hope and Healing Cancer Services — Hinsdale, Illinois
- University of Kansas Medical Center Research Institute — Kansas City, Kansas
- New England Cancer Specialists — Westbrook, Maine
- St Louis Cancer Care, Llp — Bridgeton, Missouri
- Nebraska Hematology Oncology — Lincoln, Nebraska
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada
- Hunterdon Hematology Oncology — Flemington, New Jersey
- Summit Medical Group — Florham Park, New Jersey
- Oregon Oncology Specialists — Salem, Oregon
- Vanderbilt University — Nashville, Tennessee
- Md Anderson Cancer Center — Houston, Texas
- Scott and White Memorial Hospital — Temple, Texas
- Northwest Medical Specialties — Tacoma, Washington
- Hospital Aleman — Caba,
- Instituto Alexander Fleming (Iaf) — Ciudad Autonoma Buenos Aires,
- Fundacion Cori Para La Investigacion Y Prevencion Del Cancer — La Rioja,
- Krankenhaus Der Barmherzigen Schwestern Linz — Linz,
- Medical Univeristy Vienna — Vienna,
- Hospital de Amor Barretos — Barretos,
📞 Contact the Study Coordinator
Phone: (877) 828-5568
Email: clinicaltrials@beonemed.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Metastatic Gastric Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.